NASDAQ:CDXS - Codexis Stock Price, Forecast & News

Codexis trades on the NASDAQ under the ticker symbol "CDXS."

Codexis, Inc. (NASDAQ:CDXS) released its quarterly earnings data on Tuesday, November, 5th. The biotechnology company reported $0.01 earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.09) by $0.10. The biotechnology company had revenue of $21.91 million for the quarter, compared to analysts' expectations of $16.56 million. Codexis had a negative net margin of 17.85% and a negative return on equity of 15.24%. View Codexis' Earnings History.

Codexis is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Codexis.

Codexis will be holding an earnings conference call on Thursday, February 27th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

2 equities research analysts have issued twelve-month price objectives for Codexis' shares. Their forecasts range from $22.50 to $25.00. On average, they expect Codexis' stock price to reach $23.75 in the next twelve months. This suggests a possible upside of 83.4% from the stock's current price. View Analyst Price Targets for Codexis.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Codexis in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Codexis.

News stories about CDXS stock have been trending somewhat negative this week, according to InfoTrie Sentiment Analysis. InfoTrie scores the sentiment of news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Codexis earned a news sentiment score of -1.0 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 5.0 out of 10, indicating that recent news coverage is somewhat likely to have an impact on the company's share price in the next several days. View News Stories for Codexis.

Codexis saw a increase in short interest in January. As of January 31st, there was short interest totalling 5,410,000 shares, an increase of 8.4% from the January 15th total of 4,990,000 shares. Based on an average daily trading volume, of 335,000 shares, the short-interest ratio is currently 16.1 days. Approximately 10.1% of the company's stock are short sold. View Codexis' Current Options Chain.

Some companies that are related to Codexis include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), EXACT Sciences (EXAS), Alnylam Pharmaceuticals (ALNY), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Codexis investors own include Advanced Micro Devices (AMD), Canopy Growth (CGC), Micron Technology (MU), AbbVie (ABBV), Antares Pharma (ATRS), Corbus Pharmaceuticals (CRBP), Alibaba Group (BABA), Crispr Therapeutics (CRSP), Cisco Systems (CSCO) and Catalyst Pharmaceuticals (CPRX).

Codexis' stock is owned by many different of institutional and retail investors. Top institutional investors include Baillie Gifford & Co. (6.47%), William Blair Investment Management LLC (2.96%), Janus Henderson Group PLC (2.57%), Nikko Asset Management Americas Inc. (2.35%), Sumitomo Mitsui Trust Holdings Inc. (2.35%) and FMR LLC (2.33%). Company insiders that own Codexis stock include Bernard J Kelley, Byron L Dorgan, David V Smith, Dennis P Wolf, Gordon Sangster, James Lalonde, John J Nicols, Kathleen Sereda Glaub, Michael D Aldridge, Pam P Cheng, Patrick Y Yang and Thomas R Baruch. View Institutional Ownership Trends for Codexis.

CDXS stock was sold by a variety of institutional investors in the last quarter, including Lord Abbett & CO. LLC, Prescott Group Capital Management L.L.C., FMR LLC, Oak Ridge Investments LLC, Stifel Financial Corp, Sumitomo Mitsui Trust Holdings Inc., Nikko Asset Management Americas Inc. and Bank of America Corp DE. Company insiders that have sold Codexis company stock in the last year include Bernard J Kelley, Byron L Dorgan, Dennis P Wolf, Gordon Sangster, James Lalonde, John J Nicols and Thomas R Baruch. View Insider Buying and Selling for Codexis.

CDXS stock was bought by a variety of institutional investors in the last quarter, including William Blair Investment Management LLC, Baillie Gifford & Co., Janus Henderson Group PLC, Aviva PLC, Essex Investment Management Co. LLC, Goldman Sachs Group Inc., Barclays PLC and Marshall Wace LLP. Company insiders that have bought Codexis stock in the last two years include John J Nicols and Patrick Y Yang. View Insider Buying and Selling for Codexis.

Shares of CDXS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CDXS stock can currently be purchased for approximately $12.95.

Codexis has a market capitalization of $757.83 million and generates $60.59 million in revenue each year. The biotechnology company earns $-10,880,000.00 in net income (profit) each year or ($0.21) on an earnings per share basis. Codexis employs 132 workers across the globe.View Additional Information About Codexis.

The official website for Codexis is http://www.codexis.com/.

Codexis' mailing address is 200 PENOBSCOT DRIVE, REDWOOD CITY CA, 94063. The biotechnology company can be reached via phone at 650-421-8100 or via email at [email protected]